METTL3Differential Expression And Its Impact On The Prognosis Of Patients With Liver Cancer Undergoing Curative Resection

Hepatocellular carcinoma is one of the world’s most common fatal malignanttumor with a high degree of malignancy, easy to transfer and recurrence. The TNM andBCLC staging can be found in the clinical observation, but the same clinical stage of thepatient’s postoperative prognosis are different.As the main forecasting tool, especially inthe early HCC prognosis in liver cancer clinical staging system is still have somedefects in the application of liver cancer clinical staging system.So found more sensitiveespecially important clinicopathological parameters to make up for the role of molecularmarkers, combined with TNM and BCLC staging to determine the prognosis of patients,will help you choose a more reasonable treatment methods and improve the overallefficacy of liver cancer.In order to explore the molecular markers associated with liver cancerprognosis,we choose METTL3as the observed indicators.METTL3M6A is currentlythe only known component of the composition of the methyl transferase enzymecomplex informed in the process of pre-processing of mRNA, may be playing animportant role in the cells generation, proliferation and migration.This topic focuses onthe expression levels of the METTL3in particular to explore its early HCC prognosis ofhepatocellular carcinoma postoperative prognosis judgment to provide new molecularmarkers for liver cancer prognosis.METTL3differential expression and its impact on the prognosis of patientswith liver cancer undergoing curative resection。Purpose: The association between the overexpression of METTL in patients withhepatocellular carcinoma and the prognosis, especially the BCLC early (0/A) theprognosis of patients.Methods: By tissue microarray and Western blotting method and use SPSS18.0software.We retrospectively observed from2006.1-2007.6continuously293patientsenrolled in our hospital for liver cancer radical resection METTL3expression levels andprognosis in patients with hepatocellular carcinoma，40cases METTL3by RT-PCR inHCC tissues and adjacent tissues.Results: According to the level of METTL3expression in hepatocellularcarcinoma, enrolled293patients with liver cancer the124cases METTL3level highexpression, low expression METTL3169cases, the expression level associated with clinical and pathological features of patients with hepatocellular carcinoma. Furtherfound the METTL3expression level of patients with liver cancer serum AFP level,number of tumors, tumor diameter and TNM stage. Univariate analysis found METTL3expression and tumor diameter (P=0.045), number of tumors (P=0.013), portal veinthrombosis (P=0.022) and BCLC stage (P=0.036). Therefore come METTL3lowexpression may be related to the degree of malignancy of liver cancer。Multi-factorstatistical analysis found that the the METTL3affect the survival of patients withhepatocellular carcinoma were independent risk factors (hazard ratio HR,95%confidence interval, CI survival:0.581,0.409-0.824, P=0.002). BCLC0-A in patientswith METTL3high expression of patient survival than patients with low expression, theexpression level METTL3BCLC B and C of the prognosis of patients was notstatistically significant.Conclusion: Prognosis speculated METTL3play the role of tumor suppressorgenes in liver cancer patients with low expression within five years mortality wassignificantly higher than the high expression group。Specific METTL3with malignantdegree by those signal transduction pathways, and how they affect tumor cell invasionand migration, further research is needed to become therapeutic targets and other issues.